Axsome Therapeutics's market cap is currently ―. The company's EPS TTM is $-5.2; its P/E ratio is -14.05; Axsome Therapeutics is scheduled to report earnings on May 6, 2024, and the estimated EPS forecast is $-1.18. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ 71.53M	$ 57.79M	$ 46.02M	$ 94.58M	$ 24.37M
Gross Profit	$ 107.36M	$ 51.08M	$ 48.15M	$ 94.74M	$ 20.17M
EBIT	$ -94.05M	$ -57.99M	$ -63.72M	$ -12.27M	$ -54.72M
EBITDA	$ -91.83M	$ -55.62M	$ -61.44M	$ -9.71M	$ -53.11M
Net Income Common Stockholders	$ -98.65M	$ -62.56M	$ -67.17M	$ -11.22M	$ -61.24M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 386.19M	$ 416.56M	$ 437.11M	$ 246.51M	$ 200.84M
Total Assets	$ 588.24M	$ 600.86M	$ 611.64M	$ 388.48M	$ 331.48M
Total Debt	$ 186.37M	$ 185.57M	$ 184.71M	$ 147.72M	$ 94.68M
Net Debt	$ -199.82M	$ -230.99M	$ -252.40M	$ -98.79M	$ -106.16M
Total Liabilities	$ 397.26M	$ 331.35M	$ 332.83M	$ 277.37M	$ 221.92M
Stockholders Equity	$ 190.98M	$ 269.51M	$ 278.82M	$ 111.76M	$ 109.56M
Cash Flow	-
Free Cash Flow	$ -30.37M	$ -53.92M	$ -55.48M	$ -5.89M	$ -27.74M
Operating Cash Flow	$ -30.36M	$ -53.55M	$ -55.35M	$ -5.82M	$ -27.56M
Investing Cash Flow	$ -7.00K	$ -371.00K	$ -133.00K	$ -71.00K	$ -180.86K
Financing Cash Flow	$ -2.00K	$ 33.37M	$ 246.08M	$ 51.56M	$ 1.07M

Currency in USD

Axsome Therapeutics Earnings and Revenue History

Income Statement >

Axsome Therapeutics Debt to Assets

Balance Sheet >

Axsome Therapeutics Cash Flow

Cash Flow >

Axsome Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing